The effect of Galenos Barij Syrup on nausea and vomiting caused by chemotherapy with strong emetic ability compared to standard treatment.

Comparison of the effectiveness of Galenos Barij Syrup on preventing nausea and vomiting in patients referred to outpatient chemotherapy receiving the regime with high emetic chemotherapy (HEC) compared to the standard regime

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230807059069N1

Enrollment

Registered

2023-10-24

Start date

2023-09-23

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy. Encounter for Antineoplastic Chemotherapy and Immunotherapy

Interventions

Intervention 1: Intervention group: In our current study, we used 5-10 cc barrage syrup based on person weight. Barrage syrup is containing fruit (Cydonia oblonga), ginger (Zingiberofficinale), vinega

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: People over the age of 18 Patients under high emetogenic chemotherapy regimens (HEC) referring to outpatient chemotherapy at Imam Khomeini Hospital and Baghban Complex

Exclusion criteria

Exclusion criteria: Allergy to ginger Ginger consumption within a week before the start of the intervention Users of warfarin, heparin and aspirin drugs History of neurological diseases, history of seizures and epilepsy, history of blood disorders Patients with bowel obstruction or brain or bowel metastasis Lack of consent to participate in the study

Design outcomes

Primary

Measure	Time frame
The Rhodes Index questionnaire will evaluate the main outcome of the study. This tool (Nausea and Vomiting Index) is designed as a 5-point Likert scale (score 0-4). The final score range will vary between 0-32. In order to interpret the scores obtained from the questionnaire, the average scores related to nausea and vomiting in each group were calculated. The Rhodes questionnaire will be completed daily.All patients were provided with a daily side effect checklist at the first visit to the outpatient chemotherapy clinic. Using the checklist, patients will record daily their nausea with a numerical rating scale (NRS) (0-10) and the number of times or episodes of vomiting up to 7 days after chemotherapy. The physician implementing the plan will record the amount of control of nausea and vomiting in the medical record after confirming the data or hearing the results of the patients at the next visit. Complete protection from nausea (NRS <1) and vomiting (no episodes) during the acute (within 24 hours after chemotherapy) and delayed (within 2 to 7 days after chemotherapy) episodes in patients receiving the first cycle of chemotherapy or will be evaluated in general cycles of chemotherapy. Timepoint: Patients will record daily nausea (0-10) and the number of times or episodes of vomiting up to 7 days after chemotherapy. Method of measurement: Rhodes Index Questionnaire.	—

Measure

Time frame

The Rhodes Index questionnaire will evaluate the main outcome of the study. This tool (Nausea and Vomiting Index) is designed as a 5-point Likert scale (score 0-4). The final score range will vary between 0-32. In order to interpret the scores obtained from the questionnaire, the average scores related to nausea and vomiting in each group were calculated. The Rhodes questionnaire will be completed daily.All patients were provided with a daily side effect checklist at the first visit to the outpatient chemotherapy clinic. Using the checklist, patients will record daily their nausea with a numerical rating scale (NRS) (0-10) and the number of times or episodes of vomiting up to 7 days after chemotherapy. The physician implementing the plan will record the amount of control of nausea and vomiting in the medical record after confirming the data or hearing the results of the patients at the next visit. Complete protection from nausea (NRS <1) and vomiting (no episodes) during the acute (within 24 hours after chemotherapy) and delayed (within 2 to 7 days after chemotherapy) episodes in patients receiving the first cycle of chemotherapy or will be evaluated in general cycles of chemotherapy. Timepoint: Patients will record daily nausea (0-10) and the number of times or episodes of vomiting up to 7 days after chemotherapy. Method of measurement: Rhodes Index Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Mehdi Vaziri

Mazandaran University of Medical Sciences

drmmvaziri@gmail.com+98 11 3336 4044

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026